Rebecca Araujo

DocwireNews

Nimotuzumab plus gemcitabine demonstrated a favorable safety profile and significantly improved survival in patients with locally advanced or metastatic K-Ras wild-type pancreatic cancer, according to results from a randomized trial published in the <a href="https://ascopubs.org/doi/full/10.1200/JCO.22.02630" target="_blank" rel="noopener">Journal of Clinical Oncology</a>.
The study reported results from a phase 3 study to verify efficacy and safety of the nimotuzumab-plus-gemcitabine regimen in 82 patients with locally advanced or metastatic tumors. The proportion of patients with K-Ras wild-type tumors was 17.1%. Patients were randomized to either intravenous nimotuzumab (400 mg once per week) or placebo, with 41 patients per group. All patients received a regimen of gemcitabine (1000 mg/m2) on days 1, 8, and 15 for 3 weeks, followed by 1 week of rest, then once per week for 4 weeks. This treatment cycle continued until disease progression, unmanageable toxicity, or withdrawal. Follow-up continued until death or study completion.
Tumor response was evaluated by computed tomography or magnetic resonance imaging every 8 weeks. The primary end point was overall survival (OS). The secondary end points were progression-free survival (PFS), time to progression (TTP), objective response rate (ORR), and clinical benefit response.
<h2>Overall Survival Outcomes</h2>
Overall, 76 deaths occurred, including 36 in the experimental group and 40 in the placebo group. Mean follow-up time was 57.6 months and 16.6 months, respectively. Median OS was 10.9 months in the nimotuzumab group (95% CI, 5.6-16.3), compared with 8.5 months in the placebo group (95% CI, 5.7-10.0). The hazard ratio (HR) for OS in the nimotuzumab-gemcitabine group was 0.66 (95% CI, 0.42-1.05; log-rank P=.08). When utilizing a restricted mean survival time (RMST) model, OS was significantly longer in the nimotuzumab-gemcitabine group versus the placebo group at the 75-month follow-up mark (18.05 months vs 11.14 months; RMST ratio, 0.62; P=.036)
“The 1-year and 3-year OS rates were 43.6% versus 26.8% and 13.9% versus 2.7% in the investigational and control arms, respectively,” the authors wrote. “These results demonstrated that nimotuzumab increased the median survival time of patients with advanced [pancreatic cancer] with K-Ras wild-type tumors.”
<h2>Secondary Outcomes and Safety</h2>
PFS was significantly longer in the nimotuzumab treatment group. The median PFS was 4.2 months in the experimental group, compared with 3.6 months in the placebo group (HR, 0.60; 95% CI, 0.37-0.99; log-rank P=.04). At a follow-up of 31 months, the restricted mean PFS was 8.08 in the nimotuzumab group and 4.76 months in the placebo group (RMST ratio, 0.58; P=.036). Median TTP was similar between groups (4.7 months vs 3.7 months, respectively). ORRs and disease control rates (DCRs) were not significantly different between treatment groups. The ORRs were 7.3% and 9.8% in the investigation and control groups, respectively, and DCRs were 68.3% and 63.4%, respectively.
The median treatment duration was 16 weeks in the investigational group and 13 weeks in the placebo group. Median exposure dose of nimotuzumab was 6400 mg. The incidence of adverse drug reactions was similar between groups. One case of a series adverse reaction occurred in the nimotuzumab group, where a patient was hospitalized for a grade 3 bilirubin increase and anemia. No grades 4 or 5 adverse events occurred.
Compared with other studies, the authors concluded that their findings “showed that nimotuzumab might confer a remarkable survival benefit.”

Amit Goyal, MD

Magenta Elevate: Redefining Mechanical Support for High-Risk PCI

CardioNerds

Karine Tawagi, MD

What Differentiates SABCS from Other Breast Cancer Conferences?

SABCS 2024

Cecilia Brown

FDA Approves Subcutaneous Injection of Nivolumab, Hyaluronidase-nvhy for NSCLC, Other Solid Tumor Indications

Non-Small Cell Lung Cancer

Latest News

Treatment Combination Improves Survival in Advanced Pancreatic Cancer

Pancreatic Cancer

Nimotuzumab plus gemcitabine demonstrated a favorable safety profile in patients with metastatic pancreatic cancer.

Treatment Combination Improves Improves Survival in Advanced Pancreatic Cancer

About Us

Editorial Policy

Advertising

eNewsletters

Contribute

Contact Us

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Small Cell Lung Cancer

Squamous Cell Lung Carcinoma

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

The Sleep Source With Dr. Morse

The Oncology Brothers

Rheumatology Rounds With Dr. Maheswaranathan

Healthcare Unfiltered

The Fellow on Call

Partners

Hurricanes & Health Care

Career Center

Expert Interviews

Subscribe